Dry Eye – Current Treatment – Treatment Algorithms: Claims Data Analysis – Dry Eye Disease (US)
The dry eye disease (DED) market is evolving rapidly, driven by innovative treatments and a growing understanding of the condition. Historically dominated by AbbVie’s Restasis, the market has seen a surge of new FDA-approved therapies in the last five years. These agents include Alcon’s Eysuvis and Viatris / Oyster Point’s Tyrvaya with its unique intranasal delivery system. The latest entrants, Bausch + Lomb / Novaliq’s Miebo, the first and only therapy specifically approved for treating evaporative DED, and Harrow / Novaliq’s Vevye, further expand physicians’ treatment armamentarium as the only water-free, cyclosporine-based agents approved for treating both signs and symptoms of DED. Beyond conservative measures like lid hygiene and artificial tears, the management of DED also includes the prescription of off-label ophthalmic corticosteroids and antibiotics.
QUESTIONS ANSWERED
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed DED patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed DED patients?
- How has Vevye been integrated into the treatment algorithm, and what is its source of business?
- What percentage of DED patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of DED patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
Markets covered: United States
Key companies: AbbVie, Bausch + Lomb, Sun Ophthalmics, Kala Pharmaceuticals, Alcon, Viatris, Novaliq, Harrow
Key drugs: Restasis, Restasis MultiDose, Xiidra, Cequa, Eysuvis, Tyrvaya, Miebo, Vevye
PRODUCT DESCRIPTION
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:
- Understand patient flow between lines of therapy.
- Evaluate your brand share against competitors.
- Accurately assess your source of business.
- Quantify opportunities at different stages of the treatment algorithm.
Product enhancement
Treatment Algorithms: Claims Data Analysis leverages Clarivate’s proprietary Real-World Data, which brings larger patient samples, broader payer coverage, and faster availability for more robust and timely analyses. Additionally, we include new patient demographic analyses: age, gender, ethnicity, and region.
